One Solution, Five Disease Pathways: CEO Pete O'Heeron on Fibrobiologic's (Nasdaq: FBLG) Fribroblast

<p>CEO Pete O&#39;Heeron joins RedChip to explain why FibroBiologics (Nasdaq: FBLG) believes fibroblasts, not stem cells, represent the next major platform in regenerative medicine.FibroBiologics is a clinical-stage biotech built around a simple but underappreciated fact: fibroblasts, the cell type behind Dr. Shinya Yamanaka&#39;s Nobel Prize-winning discovery of induced pluripotent stem cells, appear to be more potent and more immune-modulating than the stem cells they helped create. They also outnumber stem cells roughly 5,000 to 1 in the human body. Rather than building around a single drug candidate, as many biotech companies do, FibroBiologics has used that abundance to construct a multi-program platform spanning wound care, orthopedics, autoimmune disease, oncology, and thymus regeneration — an approach O&#39;Heeron says has produced clinical-stage success across every therapeutic pathway the company has pursued.The company&#39;s furthest-along program targets diabetic foot ulcers, where O&#39;Heeron says fibroblasts do what they do best: heal wounds. It&#39;s a 12-week trial designed to validate in the clinic what has been shown in animal studies, healing time cut in half compared to a leading wound-care product from Smith &amp; Nephew. That program sits alongside a broader pipeline spanning autoimmune disease, orthopedics, oncology, and thymus regeneration. The company says it has seen clinical success on every therapeutic pathway it has pursued so far. Its intellectual property position underpins that breadth: more than 250 patents issued and pending, covering therapeutic use of fibroblasts.👉 FibroBiologics is a client of RedChip. To learn more about FBLG and to read our full disclosure, visit: https://www.FBLGinfo.com#FBLG #FibroBiologics #Fibroblasts #CellTherapy #RegenerativeMedicine #StemCellAlternative #DiabeticFootUlcers #MultipleSclerosis #WoundCare #Biotech #SmallCapStocks #Nasdaq #InvestorEducation #StockInterviews</p>